August 31, 2020 09:29 AM EDTUpdated 09:52 AM
R&D

As­traZeneca looks to widen its lead over SGLT2 ri­vals with an­oth­er round of land­mark da­ta

Nicole DeFeudis

Editor

Com­pe­ti­tion be­tween SGLT2 in­hibitors in the chron­ic kid­ney dis­ease field just got more in­ter­est­ing. This week­end, As­traZeneca went to the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy’s 2020 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times